Drug–gene and drug–drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial
dc.contributor.author | Fulton, Cathy R. | |
dc.contributor.author | Zang, Yong | |
dc.contributor.author | Desta, Zeruesenay | |
dc.contributor.author | Rosenman, Marc B. | |
dc.contributor.author | Holmes, Ann M. | |
dc.contributor.author | Decker, Brian S. | |
dc.contributor.author | Zhang, Yifei | |
dc.contributor.author | Callaghan, John T. | |
dc.contributor.author | Pratt, Victoria M. | |
dc.contributor.author | Levy, Kenneth D. | |
dc.contributor.author | Gufford, Brandon T. | |
dc.contributor.author | Dexter, Paul R. | |
dc.contributor.author | Skaar, Todd C. | |
dc.contributor.author | Eadon, Michael T. | |
dc.contributor.department | Medicine, School of Medicine | en_US |
dc.date.accessioned | 2020-06-24T16:59:08Z | |
dc.date.available | 2020-06-24T16:59:08Z | |
dc.date.issued | 2019-04 | |
dc.description.abstract | Background: Tramadol and codeine are metabolized by CYP2D6 and are subject to drug-gene and drug-drug interactions. Methods: This interim analysis examined prescribing behavior and efficacy in 102 individuals prescribed tramadol or codeine while receiving pharmaco-genotyping as part of the INGENIOUS trial (NCT02297126). Results: Within 60 days of receiving tramadol or codeine, clinicians more frequently prescribed an alternative opioid in ultrarapid and poor metabolizers (odds ratio: 19.0; 95% CI: 2.8-160.4) as compared with normal or indeterminate metabolizers (p = 0.01). After adjusting the CYP2D6 activity score for drug-drug interactions, uncontrolled pain was reported more frequently in individuals with reduced CYP2D6 activity (odds ratio: 0.50; 95% CI: 0.25-0.94). Conclusion: Phenoconversion for drug-drug and drug-gene interactions is an important consideration in pharmacogenomic implementation; drug-drug interactions may obscure the potential benefits of genotyping. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Fulton, C. R., Zang, Y., Desta, Z., Rosenman, M. B., Holmes, A. M., Decker, B. S., Zhang, Y., T Callaghan, J., Pratt, V. M., Levy, K. D., Gufford, B. T., Dexter, P. R., Skaar, T. C., & Eadon, M. T. (2019). Drug-gene and drug-drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial. Pharmacogenomics, 20(6), 397–408. https://doi.org/10.2217/pgs-2018-0205 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/23075 | |
dc.language.iso | en_US | en_US |
dc.publisher | Future Medicine | en_US |
dc.relation.isversionof | 10.2217/pgs-2018-0205 | en_US |
dc.relation.journal | Pharmacogenomics | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | Adverse side effects | en_US |
dc.subject | CYP2D6 | en_US |
dc.subject | IGNITE | en_US |
dc.subject | INGENIOUS | en_US |
dc.subject | Pharmacogenetics | en_US |
dc.subject | Opioids | en_US |
dc.subject | Pharmacogenomics | en_US |
dc.subject | Phenoconversion | en_US |
dc.title | Drug–gene and drug–drug interactions associated with tramadol and codeine therapy in the INGENIOUS trial | en_US |
dc.type | Article | en_US |
ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562829/ | en_US |